2. UroToday Home
  3. Categories

Renal Cancer

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium - Beyond the Abstract

Details
The treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved dramatically with the introduction of immune checkpoint inhibitor-based combinations, leading to an increasing number of patients achieving complete responses (CR). While CR is often perceived as a surrogate for cure, its true clinical meaning in routine practice remains uncertain.

Sutureless Robotic-Assisted Partial Nephrectomy: A Propensity Score-Matched Analysis (UroCCR N.158) - Beyond the Abstract

Details
Partial nephrectomy remains the standard of care for T1 renal tumors, and indications are increasingly expanding to more complex cases. Historically, renorrhaphy was considered a mandatory step to ensure hemostasis and secure the urinary collecting system. However, emerging data suggest that parenchymal compression may be deleterious, inducing local ischemia and the loss of functional nephrons. With the rise of robotic platforms, we explored a more minimalist philosophy: once definitive hemostasis is achieved, is suturing truly necessary?

Cancer-Associated Fibroblasts Promote Development of Papillary Renal Cell Carcinoma by Inducing Histone Lactylation of RBM15B to Modify in an m6A-Dependent Manner on ANLN.

Details

Renal papillary cell carcinoma (pRCC) is a prevalent subtype of kidney cancer with unclear pathogenesis and limited therapeutic options. The Anillin protein plays critical roles in cell division and cytoskeleton organization; it has not been fully explored in pRCC.

Comparative effectiveness and cost-effectiveness of an artificial intelligence workflow for small renal mass diagnosis on computed tomography.

Details

Small renal masses are increasingly detected on imaging, but their accurate classification as benign, indolent, or aggressive remains challenging. Such classification can aid further diagnostic work up, improving patient outcomes and saving costs.

Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes.

Details

Introduction Immune checkpoint inhibitors have transformed the treatment of metastatic renal cell carcinoma (RCC). Whether these advances translated into population-level survival improvements across histologic subtypes remains uncertain.

Co-overexpression of ELOVL2 and ELOVL5 promotes clear cell renal cell carcinoma progression through LIMK1-mediated cytoskeletal reorganization.

Details

Clear cell renal cell carcinoma (ccRCC) frequently exhibits dysregulated lipid metabolism yet the contribution of polyunsaturated fatty acid (PUFA) elongation to malignant phenotypes remains incompletely defined.

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Details

Frontline systemic therapy for metastatic clear cell renal cell carcinoma (RCC) has evolved to include doublet immunotherapy (IO/IO) and immunotherapy-tyrosine kinase inhibitor combinations (IO/TKI), with selection typically guided by histology and risk stratification.

Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity.

Details

Robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) are established treatment options for localized renal tumors. While RAPN remains the standard-of-care, PTA is increasingly adopted, particularly in patients unfit for surgery.

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Details

Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in advanced renal cell carcinoma (RCC). However, real-world evidence regarding its safety profile, particularly sex-specific adverse events (AEs) and cardiovascular toxicity, remains limited.

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma.

Details

Despite not achieving statistical significance, the JAVELIN Renal 101 trial indicated a potentially clinically relevant effect size (hazard ratio [HR], 0.88; 95% confidence interval, 0.75 to 1.04) on overall survival (OS) favoring avelumab plus axitinib over sunitinib for advanced renal cell carcinoma (aRCC).

Page 1 of 1033